Recruiting Advanced Solid Tumors Studies in Fuzhou
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic s...
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions...
About Advanced Solid Tumors Clinical Trials in Fuzhou
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 2 advanced solid tumors clinical trials recruiting participants in Fuzhou, FUJIAN. These studies are seeking a combined 212 participants. Research is being sponsored by Adagene Inc, Teligene US. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Fuzhou — FAQ
Are there advanced solid tumors clinical trials in Fuzhou?
Yes, there are 2 advanced solid tumors clinical trials currently recruiting in Fuzhou, FUJIAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Fuzhou?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fuzhou research site will contact you about next steps.
Are clinical trials in Fuzhou free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fuzhou studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 2 active trials in Fuzhou are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov